These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 11178412)

  • 1. Development of the human monoclonal antibodies.
    Lindl T
    ALTEX; 1995; 12(1):13-23. PubMed ID: 11178412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of human monoclonal antibodies. Current status and future development].
    Gebauer W; Lindl T
    Arzneimittelforschung; 1989 Feb; 39(2):287-91. PubMed ID: 2659004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of human monoclonal antibodies: A review.
    Lindl T
    Cytotechnology; 1996 Jan; 21(3):183-93. PubMed ID: 22358750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
    Ohlin M; Broliden PA; Danielsson L; Wahren B; Rosen J; Jondal M; Borrebaeck CA
    Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Epstein-Barr virus transformation for the production of human monoclonal antibodies.
    Roome AJ; Reading CL
    Exp Biol; 1984; 43(1):35-55. PubMed ID: 6099808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro generated human monoclonal trinitrophenyl-specific B cell lines. Evidence that human and murine anti-trinitrophenyl monoclonal antibodies cross-react with Escherichia coli beta-galactosidase.
    Golding B; Inghirami G; Peters E; Hoffman T; Balow JE; Tsokos GC
    J Immunol; 1987 Dec; 139(12):4061-6. PubMed ID: 2826579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation.
    Gebauer W; Lindl T
    Arzneimittelforschung; 1990 Jun; 40(6):718-22. PubMed ID: 2168706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies: methods and clinical laboratory applications.
    Nakamura RM
    Clin Physiol Biochem; 1983; 1(2-5):160-72. PubMed ID: 6396016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of anti-tumor human monoclonal antibodies using different approaches.
    Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies.
    van de Griend RJ; Giphart MJ; Van Krimpen BA; Bolhuis RL
    J Immunol; 1984 Sep; 133(3):1222-9. PubMed ID: 6205072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
    Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
    Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies produced by human-human hybridomas].
    Chida J
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):157-64. PubMed ID: 6607711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From host components of virus particles to anti-myelin human monoclonal antibodies obtained by Epstein-Barr virus transformation of lymphocytes from multiple sclerosis patients.
    Dernick R; Uhlig H
    Behring Inst Mitt; 1991 Jul; (89):138-45. PubMed ID: 1656931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
    Kuljić-Kapulica N
    Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of human monoclonal antibodies to B lymphocyte cell surface antigens by in vitro immunization and human-human hybridoma technology.
    Power DA; Gerkis V; d'Apice AJ
    Hum Antibodies Hybridomas; 1990; 1(1):34-41. PubMed ID: 2103351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
    Tong AW; Lee J; Stone MJ
    Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.